Icahn Reacts Audaciously To Illumina’s Audacity

Carl Icahn has correctly diagnosed what ails Illumina, but he is prescribing an overly aggressive treatment. The pushy billionaire wants three board seats at the biotechnology company, after it overpaid for Grail and took on too much regulatory risk.